Moreover, the impact of incretin hormones such as GLP1 and GIP on both insulin secretion and satiety has been widely reported (Baggio and Drucker, 2007), with GLP1-agonists now being regularly employed in the treatment of type 2 diabetes mellitus (Man et al., 2009). Here, GIP is linked to diabetes mellitus.